Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.
about
Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC)Tumor and stromal-based contributions to head and neck squamous cell carcinoma invasionProtein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancerIn silico investigation of potential SRC kinase ligands from traditional Chinese medicineInhibiting tyrosine phosphorylation of protein kinase Cδ (PKCδ) protects the salivary gland from radiation damageCytotoxic effects of 15-deoxy-Δ12,14-prostaglandin J2 alone and in combination with dasatinib against uterine sarcoma in vitro.Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium.Src family kinases and paclitaxel sensitivity.STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous carcinomaDasatinib suppresses invasion and induces apoptosis in nasopharyngeal carcinoma.Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met.Antitumor effects of Dasatinib on laryngeal squamous cell carcinoma in vivo and in vitro.Comprehensive Characterization of Molecular Differences in Cancer between Male and Female PatientsDasatinib Inhibits DNA Repair after Radiotherapy Specifically in pSFK-Expressing Tumor Areas in Head and Neck Xenograft Tumors.Increased killing of SCCVII squamous cell carcinoma cells after the combination of Pc 4 photodynamic therapy and dasatinib is associated with enhanced caspase-3 activity and ceramide synthase 1 upregulation.Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines.Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop.Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress.Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancerNovel anti-cancer compounds for developing combinatorial therapies to target anoikis-resistant tumors.Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistanceEmerging tyrosine kinase inhibitors for head and neck cancer.Pharmacology of Src family kinases and therapeutic implications of their modulators.Molecular biology and immunology of head and neck cancer.Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib.The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma.Targeting the Tumor Environment in Squamous Cell Carcinoma of the Head and Neck.Benefits of Multifaceted Chemopreventives in the Suppression of the Oral Squamous Cell Carcinoma (OSCC) Tumorigenic Phenotype.An immunosuppressive antibody-drug conjugate.Biologic therapy in head and neck cancer: a road with hurdles.Emerging drugs for head and neck cancer.Tyrosine Kinase Inhibitors Protect the Salivary Gland from Radiation Damage by Inhibiting Activation of Protein Kinase C-δ.IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.
P2860
Q26765429-4CF6693D-61A0-4E35-B4C0-2A64E9F440F5Q26825164-1CF76176-2847-4E64-A3DC-79C12E97EE17Q26852215-8C852F13-54C0-4C68-BB3C-409551F36836Q28481644-410E32F3-F6C1-4FBE-BF82-55654D8F476AQ33675916-E6638556-41B4-483A-9531-7366B54FDCCFQ33744855-DE43E03E-09E6-46BA-B0A1-F118E90CECC5Q33924908-5B998844-A1D9-434D-B5C6-CC80DE36332BQ35050239-71075B12-ECCE-4349-8892-FDA6049B0A6EQ35214722-7215EB01-0D97-46F8-B810-F4AB989444BDQ35653082-D273575D-8CD9-4901-95C6-233207074482Q36014173-D5572CE7-C0C0-43C3-AAA0-A6826EC48246Q36088163-4FF7F9BB-31C1-4F39-B52E-BBD4F0FD7579Q36430737-646F63CE-43C8-4B50-99E6-2811480DF736Q36545205-7AF99E58-D4BC-45FB-8780-A891C84D3197Q36718435-854DA1E1-DF2C-42A7-B5D5-10A1BC85D1BCQ36895507-75131824-525A-42F0-853D-75DC12971F73Q37060946-41E351F1-6779-4C93-96D3-45AA8A2FE681Q37326151-997FEB75-AAE8-4B55-B885-3AB84F9C1907Q37347999-265F75C2-FDC6-4B26-B0AC-582FC06C5A05Q37494943-4D6BD0F6-7316-4C8A-9F7C-EFB425D13039Q37649672-FB68ED97-3F4A-4A4A-AEFF-5A97596F0958Q37711811-FC9EF503-8AC7-4C79-9FB2-54D463EB2747Q37971860-79C083D6-61B1-4B13-A12A-1AC5ACB3BD0EQ37995872-0A737A42-96B2-47E7-9C47-55570B0A7C0AQ38118934-0CB3E353-1E46-4EBE-8353-686D96C60EF6Q38149327-EA99B50A-C60F-429B-9FFC-F5262E003205Q38302202-2A9A5845-3C15-4679-8950-3074153212C5Q38483321-777AAE09-0BCA-40CA-B0F0-2C3F0D0B5AADQ38756969-19BD9CEF-444E-4829-8DE8-421A32052EF8Q38768576-2549303D-B4CE-42AE-A076-64E42879906CQ38815335-48438FC0-FC70-4584-90EA-6676A2B2C799Q38855031-16338D4D-61DE-4309-967D-AE6169B92C84Q41070558-756D3793-6652-4A45-A09E-4F9B4F8613C5Q42207099-0486A548-BEB3-4FCB-806E-A9CA5EE295E3Q42213295-44536950-8F89-4960-87D6-E310D2E9B621Q45874449-7FCA6D97-6033-4478-92B9-7096704C09A5Q50931131-6C1D2DF1-84D0-40F7-A83C-FE0C0EB066C1Q53258023-AF15E915-EC07-430C-BFF5-DCB6E9CA3C22
P2860
Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.
@ast
Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.
@en
type
label
Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.
@ast
Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.
@en
prefLabel
Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.
@ast
Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.
@en
P2093
P2860
P356
P1433
P1476
Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.
@en
P2093
Adel El-Naggar
B Nebiyou Bekele
Bonnie S Glisson
Faye M Johnson
Hai T Tran
Heather D Brooks
John Wright
Kirk S Culotta
Lawrence E Ginsberg
Naoko Takebe
P2860
P304
P356
10.1002/CNCR.25769
P407
P577
2010-11-29T00:00:00Z